Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma

Abstract Purpose This study aimed to analyze the prognostic and diagnostic value of Lactate dehydrogenase A (LDHA) and solute carrier family 16 member 1 (SLC16A1) in low-grade gliomas (LGG). Methods Gene expression datasets for LGG were downloaded from The Cancer Genome Atlas (TCGA), Chinese Glioma...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingyi Huang, Qishun Wang, Zhijun Li, Xuning Huang, Wen Wang, Jiao Liu
Format: Article
Language:English
Published: Springer 2025-08-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-03297-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849234755643506688
author Jingyi Huang
Qishun Wang
Zhijun Li
Xuning Huang
Wen Wang
Jiao Liu
author_facet Jingyi Huang
Qishun Wang
Zhijun Li
Xuning Huang
Wen Wang
Jiao Liu
author_sort Jingyi Huang
collection DOAJ
description Abstract Purpose This study aimed to analyze the prognostic and diagnostic value of Lactate dehydrogenase A (LDHA) and solute carrier family 16 member 1 (SLC16A1) in low-grade gliomas (LGG). Methods Gene expression datasets for LGG were downloaded from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO) databases. The prognostic value of LDHA and SLC16A1 in LGG was analyzed using the survival package. Receiver operating characteristic (ROC) curves were drawn to evaluate the ability of the model to distinguish between patients with LGG and controls. Gene set enrichment analysis (GSEA) of single gene was utilized to explore the potential biological function of the two genes. The protein levels of LDHA and SLC16A1 were analyzed using the Human Protein Atlas database. LDHA and SLC16A1 expression was verified using real-time reverse transcription polymerase chain reaction. Finally, the effects of low SLC16A1 expression on the proliferation, migration, and invasion of LGG cells were investigated using CCK-8 and Transwell assays. Results LDHA was downregulated, and SLC16A1 was upregulated in LGG tissues compared to normal tissues in TCGA dataset. Kaplan–Meier (K–M) survival and ROC curves revealed that these two genes have potential prognostic and diagnostic performances. LDHA positively correlated with SLC16A1 in TCGA and CGGA cohorts. GSEA demonstrated that LDHA is involved in the chemokine and NOD-like receptor signaling pathways, whereas SLC16A1 is involved in the JAK-STAT and NOD-like receptor signaling pathways. Immunohistochemical profiles of LDHA and SLC16A1 were consistent with their mRNA expression levels. SLC16A1 overexpression and downregulation of LDHA have been validated in glioma cell lines. Additionally, low SLC16A1 expression inhibited the proliferation, migration, and invasion of glioma cells. Conclusion LDHA and SLC16A1 have potential prognostic and diagnostic values for LGG. Therefore, SLC16A1 may serve as a potential biomarker for the diagnosis and treatment of LGG.
format Article
id doaj-art-32d50244e001443cb04bd9a86c4bbfcd
institution Kabale University
issn 2730-6011
language English
publishDate 2025-08-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-32d50244e001443cb04bd9a86c4bbfcd2025-08-20T04:03:02ZengSpringerDiscover Oncology2730-60112025-08-0116111610.1007/s12672-025-03297-2Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade gliomaJingyi Huang0Qishun Wang1Zhijun Li2Xuning Huang3Wen Wang4Jiao Liu5Human Anatomy and Histoembryology, Shandong Second Medical UniversityDepartment of Surgery, Changyi City Hospital of Traditional Chinese MedicineChangyi City Center for Disease Control and PreventionChangyi City Hospital of Traditional Chinese Medicine PharmacyDepartment of Internal Medicine, Changyi City Hospital of Traditional Chinese MedicineSchool of Basic Medicine Sciences, Shandong Second Medical UniversityAbstract Purpose This study aimed to analyze the prognostic and diagnostic value of Lactate dehydrogenase A (LDHA) and solute carrier family 16 member 1 (SLC16A1) in low-grade gliomas (LGG). Methods Gene expression datasets for LGG were downloaded from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO) databases. The prognostic value of LDHA and SLC16A1 in LGG was analyzed using the survival package. Receiver operating characteristic (ROC) curves were drawn to evaluate the ability of the model to distinguish between patients with LGG and controls. Gene set enrichment analysis (GSEA) of single gene was utilized to explore the potential biological function of the two genes. The protein levels of LDHA and SLC16A1 were analyzed using the Human Protein Atlas database. LDHA and SLC16A1 expression was verified using real-time reverse transcription polymerase chain reaction. Finally, the effects of low SLC16A1 expression on the proliferation, migration, and invasion of LGG cells were investigated using CCK-8 and Transwell assays. Results LDHA was downregulated, and SLC16A1 was upregulated in LGG tissues compared to normal tissues in TCGA dataset. Kaplan–Meier (K–M) survival and ROC curves revealed that these two genes have potential prognostic and diagnostic performances. LDHA positively correlated with SLC16A1 in TCGA and CGGA cohorts. GSEA demonstrated that LDHA is involved in the chemokine and NOD-like receptor signaling pathways, whereas SLC16A1 is involved in the JAK-STAT and NOD-like receptor signaling pathways. Immunohistochemical profiles of LDHA and SLC16A1 were consistent with their mRNA expression levels. SLC16A1 overexpression and downregulation of LDHA have been validated in glioma cell lines. Additionally, low SLC16A1 expression inhibited the proliferation, migration, and invasion of glioma cells. Conclusion LDHA and SLC16A1 have potential prognostic and diagnostic values for LGG. Therefore, SLC16A1 may serve as a potential biomarker for the diagnosis and treatment of LGG.https://doi.org/10.1007/s12672-025-03297-2Lower-grade gliomaLDHASLC16A1PrognosisDiagnosis
spellingShingle Jingyi Huang
Qishun Wang
Zhijun Li
Xuning Huang
Wen Wang
Jiao Liu
Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma
Discover Oncology
Lower-grade glioma
LDHA
SLC16A1
Prognosis
Diagnosis
title Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma
title_full Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma
title_fullStr Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma
title_full_unstemmed Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma
title_short Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma
title_sort identification and validation of ldha and slc16a1 for predicting prognosis and diagnosis in lower grade glioma
topic Lower-grade glioma
LDHA
SLC16A1
Prognosis
Diagnosis
url https://doi.org/10.1007/s12672-025-03297-2
work_keys_str_mv AT jingyihuang identificationandvalidationofldhaandslc16a1forpredictingprognosisanddiagnosisinlowergradeglioma
AT qishunwang identificationandvalidationofldhaandslc16a1forpredictingprognosisanddiagnosisinlowergradeglioma
AT zhijunli identificationandvalidationofldhaandslc16a1forpredictingprognosisanddiagnosisinlowergradeglioma
AT xuninghuang identificationandvalidationofldhaandslc16a1forpredictingprognosisanddiagnosisinlowergradeglioma
AT wenwang identificationandvalidationofldhaandslc16a1forpredictingprognosisanddiagnosisinlowergradeglioma
AT jiaoliu identificationandvalidationofldhaandslc16a1forpredictingprognosisanddiagnosisinlowergradeglioma